Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: Results of a pooled subgroup analysis from three randomized, controlled, double-blind trials

American Journal of Cardiovascular Drugs

Volumn 10, Issue 2, 2010, Pages 73-84

  Jones, Peter H ^a   Cusi, Kenneth ^b   Davidson, Michael H ^c   Kelly, Maureen T ^d   Setze, Carolyn M ^d   Thakker, Kamlesh ^d   Sleep, Darryl J ^d   Stolzenbach, James C ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; ATORVASTATIN; FENOFIBRIC ACID; GLIPIZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; TRILIPIX; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT;

EID: 77950127995     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/10061630-000000000-00000     Document Type: Article

References (31)

1. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec 17; 106 (25): 3143-3221
2. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008 Apr; 31 (4): 811-822
3. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009 Jan; 32 Suppl. 1: S13-61
4. Assmann G, Schulte H, von Eckardstein A, et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996 Jul; 124 Suppl.: S11-20
5. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007 Jan 30; 115 (4): 450-458
6. Stanek EJ, Sarawate C, Willey VJ, et al. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin 2007 Mar; 23 (3): 553-563
7. Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009 Mar; 32 (3): 493-498
8. Alsheikh-Ali AA, Lin JL, Abourjaily P, et al. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents. Am J Cardiol 2006 Nov 1; 98 (9): 1231-1233
9. Stacy TA, Egger A. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. J Manag Care Pharm 2006 Nov-Dec; 12 (9): 745-751
10. Toth PP, Zarotsky V, Sullivan JM, et al. Lipid therapy utilization rates in a managed-care mixed dyslipidemia population. J Clin Lipidol 2008; 2: 365-374
11. Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 2009; 103: 515-522
12. Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 2009 May; 204 (1): 208-215
13. Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J 2009 Jan; 157 (1): 195-203
14. Jones PH, Bays HE, Davidson MH, et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins. Clin Drug Invest 2008; 28 (10): 625-634
15. Bays HE, Jones PH, Mohiuddin SM, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol 2008; 2: 426-435
16. Jones PH, Davidson MH, Goldberg AC, et al. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: pooled analysis of three phase 3, 12-week, randomized, controlled studies. J Clin Lipidol 2009 April; 3 (2): 125-137
17. Durrington PN, Tuomilehto J, Hamann A, et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2004 May; 64 (2): 137-151
18. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005 May 17; 45 (10): 1649-1653
19. Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003 Apr 15; 91 (8): 956-960
20. Farnier M, Freeman MW, Macdonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005 May; 26 (9): 897-905
21. Farnier M, Roth E, Gil-Extremera B, et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J 2007 Feb; 153 (2): 335 e1-8
22. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005 Nov 26; 366 (9500): 1849-1861
23. Hiukka A, Leinonen E, Jauhiainen M, et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 2007 Oct; 50 (10): 2067-2075
24. Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009 Oct; 32 (10): 1924-1929
25. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 Nov 20; 359 (21): 2195-2207
26. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001 Jan 23; 103 (3): 357-362
27. Szendroedi J, Anderwald C, Krssak M, et al. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. Diabetes Care 2009 Feb; 32 (2): 209-214
28. Kudolo GB, Bressler P, DeFronzo RA. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment. J Lipid Mediat Cell Signal 1997 Nov; 17 (2): 97-113
29. Pruski M, Krysiak R, Okopien B. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care 2009 Aug; 32 (8): 1421-1424
30. Tenenbaum A, Fisman EZ, Boyko V, et al. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006 Apr 10; 166 (7): 737-741
31. Belfort R, Berria R, Cornell J, et al. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab Jan 8, 2010 doi:10.1210/jc.2009-1487